MIRMAID: A Content Management System for Medical Image Analysis Research.

Today, a typical clinical study can involve thousands of participants, with imaging data acquired over several time points across multiple institutions. The additional associated information (metadata) accompanying these data can cause data management to be a study-hindering bottleneck. Consistent data management is crucial for large-scale modern clinical imaging research studies. If the study is to be used for regulatory submissions, such systems must be able to meet regulatory compliance requirements for systems that manage clinical image trials, including protecting patient privacy. Our aim was to develop a system to address these needs by leveraging the capabilities of an open-source content management system (CMS) that has a highly configurable workflow; has a single interface that can store, manage, and retrieve imaging-based studies; and can handle the requirement for data auditing and project management. We developed a Web-accessible CMS for medical images called Medical Imaging Research Management and Associated Information Database (MIRMAID). From its inception, MIRMAID was developed to be highly flexible and to meet the needs of diverse studies. It fulfills the need for a complete system for medical imaging research management.

Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Determining whether glioblastoma multiforme (GBM) is progressing despite treatment is challenging due to the pseudoprogression phenomenon seen on conventional MRIs, but relative cerebral blood volume (CBV) has been shown to be helpful. As CBV's calculation from perfusion-weighted images is not standardized, we investigated whether there were differences between three FDA-cleared software packages in their CBV output values and subsequent performance regarding predicting survival/progression. Forty-five postradiation therapy GBM cases were retrospectively identified as having indeterminate MRI findings of progression versus pseudoprogression. The dynamic susceptibility contrast MR images were processed with different software and three different relative CBV metrics based on the abnormally enhancing regions were computed. The intersoftware intraclass correlation coefficients were 0.8 and below, depending on the metric used. No statistically significant difference in progression determination performance was found between the software packages, but performance was better for the cohort imaged at 3.0 T versus those imaged at 1.5 T for many relative CBV metric and classification criteria combinations. The results revealed clinically significant variation in relative CBV measures based on the software used, but minimal interoperator variation. We recommend against using specific relative CBV measurement thresholds for GBM progression determination unless the same software or processing algorithm is used.